# FDA Selects Dexcom as First Participant in TEMPO Digital Health Pilot Linked to CMS ACCESS Model

> fda · REPORTED · 2026-07-31

The FDA selected Dexcom's Glucose Health Program as the inaugural participant in its TEMPO pilot, a new framework designed to evaluate AI-enabled digital health technologies in routine care alongside the CMS ACCESS Model, whose first cohort began enrolling in July 2026. The program links recurring payments to measurable patient outcomes in prediabetes, type 2 diabetes, and cardio-kidney-metabolic conditions.

About Dexcom: Dexcom develops continuous glucose monitoring systems and AI-powered digital health programs that help patients and clinicians monitor metabolic health in real time.

- Company: Dexcom
- Sector: digital health
- Primary source: https://med-tech.world/news/fda-selects-dexcom-first-tempo-digital-health-pilot/

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.